Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory News, In Brief

Executive Summary

Compounding remains in the news as FDA issues a ‘483 report for the compounding pharmacy behind the fungal meningitis outbreak and as KV Pharmaceuticals tries to block importation of compounded versions of Makena. Other regulatory developments include a settlement over Boehringer’s off-label promotion and a further setback for Watson’s Prochieve.


Related Content

Watson May Bypass Progesterone Gel 8% For Second-Generation Product
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Watson Pulls Prochieve From Guidance, But Pushes For Approval

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts